PMID- 15296469
OWN - NLM
STAT- MEDLINE
DCOM- 20040928
LR  - 20190906
IS  - 0804-4643 (Print)
IS  - 0804-4643 (Linking)
VI  - 151
IP  - 2
DP  - 2004 Aug
TI  - Is growth hormone deficiency contributing to heart failure in patients with 
      beta-thalassemia major?
PG  - 161-6
AB  - A 21-year-old woman with beta-thalassemia major (beta-TM) and GH deficiency 
      developed end-stage heart failure, New York Heart Association (NYHA) functional 
      class IV, within 3 months after withdrawal of recombinant human growth hormone 
      (GH). A myocardial biopsy excluded myocarditis and showed moderate iron deposit 
      in the heart. Before her admission, intensified treatments with digoxin, 
      angiotensin-converting enzyme inhibitor, diuretics and extra chelation therapy 
      (desferrioxamine (DFO)) had not improved her progressive heart failure. At 
      admission, GH was reinstituted together with intensified treatment of cardiac 
      drugs and low doses of DFO, and her heart failure reversed. Four months later, 
      NYHA functional class II was reached and within 1 year her cardiac function was 
      normalised. We suggest that GH deficiency due to iron-induced damage to the 
      hypothalamic-pituitary axis can contribute to heart failure in adult patients 
      with beta-TM.
FAU - Erfurth, Eva Marie
AU  - Erfurth EM
AD  - Department of Endocrinology, Lund University Hospital, Lund, Sweden. 
      Eva_Marie.Erfurth@med.lu.se
FAU - Holmer, Helene
AU  - Holmer H
FAU - Nilsson, Per-Gunnar
AU  - Nilsson PG
FAU - Kornhall, Bjorn
AU  - Kornhall B
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Iron Chelating Agents)
RN  - 12629-01-5 (Human Growth Hormone)
RN  - J06Y7MXW4D (Deferoxamine)
SB  - IM
MH  - Adult
MH  - Cardiotonic Agents/therapeutic use
MH  - Deferoxamine/therapeutic use
MH  - Female
MH  - Heart Failure/*complications/drug therapy/*physiopathology
MH  - Human Growth Hormone/*deficiency
MH  - Humans
MH  - Iron Chelating Agents/therapeutic use
MH  - beta-Thalassemia/*complications/drug therapy/*physiopathology
EDAT- 2004/08/07 05:00
MHDA- 2004/09/29 05:00
CRDT- 2004/08/07 05:00
PHST- 2004/08/07 05:00 [pubmed]
PHST- 2004/09/29 05:00 [medline]
PHST- 2004/08/07 05:00 [entrez]
AID - 10.1530/eje.0.1510161 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 2004 Aug;151(2):161-6. doi: 10.1530/eje.0.1510161.